An update on the safety of tacrolimus in kidney transplant recipients, with a focus on tacrolimus minimization

References

• Venkat VL, Nick TG, Wang Y, et al. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence. Pediatr Transplant. 2008;12(1):67–72.
   PubMed Web of Science ®Google Scholar
• Sikma MA, Hunault CC, Kirkels JH, et al. Association of whole blood tacrolimus concentrations with kidney injury in heart transplantation patients. Eur J Drug Metab Pharmacokinet. 2018;43(3):311–320.
   PubMed Web of Science ®Google Scholar
• Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol. 2017;73(5):573–580.
   PubMed Web of Science ®Google Scholar
• Hao JC, Wang WT, Yan LN, et al. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation. World J Gastroenterol. 2014;20(32):11356–11362.
   PubMed Web of Science ®Google Scholar
• Hricik DE, Formica RN, Nickerson P, et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J Am Soc Nephrol. 2015;26(12):3114–3122.
   PubMed Web of Science ®Google Scholar
• Dugast E, Soulillou JP, Foucher Y, et al. Failure of calcineurin inhibitor (Tacrolimus) weaning randomized trial in long-term stable kidney transplant recipients. Am J Transplant. 2016;16(11):3255–3261.
   PubMed Web of Science ®Google Scholar
• Sawinski D, Trofe-Clark J, Leas B, et al. Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis. Am J Transplant. 2016;16(7):2117–2138.
   PubMed Web of Science ®Google Scholar
• Davis S, Gralla J, Klem P, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018;18(4):907–915.
   PubMed Web of Science ®Google Scholar
• Macdonald AS. Use of mTOR inhibitors in human organ transplantation. Expert Rev Clin Immunol. 2007;3(3):423–436.
   PubMedGoogle Scholar
• Piao SG, Lim SW, Doh KC, et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014;98(1):22–28.
   PubMed Web of Science ®Google Scholar
• Jouve T, Rostaing L, Malvezzi P. Place of mTOR inhibitors in management of BKV infection after kidney transplantation. J Nephropathol. 2016;5(1):1–7.
   PubMedGoogle Scholar
• Malvezzi P, Jouve T, Rostaing L. Use of everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant. Exp Clin Transplant. 2016;14(4):361–366.
   PubMed Web of Science ®Google Scholar
• Pascual J, Royuela A, Fernández AM, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819–831.
   PubMed Web of Science ®Google Scholar
• Gao L, Xu F, Cheng H, et al. Comparison of sirolimus combined with tacrolimus and mycophenolate mofetil combined with tacrolimus in kidney transplantation recipients: a meta-analysis. Transplant Proc. 2018 Dec;50(10):3306–3313.
   PubMed Web of Science ®Google Scholar
• Rummo OO, Carmellini M, Rostaing L, et al. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int. 2017 Jan;30(1):83–95.
   PubMed Web of Science ®Google Scholar
• Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17(5):1358–1369.
   PubMed Web of Science ®Google Scholar
• Tönshoff B, Ettenger R, Dello Strologo L, et al. Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: results of a randomized trial. Am J Transplant. 2018 Aug 20. DOI:10.1111/ajt.15081
   PubMedGoogle Scholar
• Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979–1991.
   PubMed Web of Science ®Google Scholar
• Pollock‐BarZiv SM, Finkelstein Y, Manlhiot C, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010;14(8):968–975.
   PubMed Web of Science ®Google Scholar
• Borra LCP, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25(8):2757–2763.
   PubMed Web of Science ®Google Scholar
• Ro H, Min S-I, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34(6):680–685.
   PubMed Web of Science ®Google Scholar
• Sapir-Pichhadze R, Wang Y, Famure O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85(6):1404–1411.
   PubMed Web of Science ®Google Scholar
• Shuker N, Shuker L, van Rosmalen J, et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. Transpl Int. 2016;29(11):1158–1167.
   PubMed Web of Science ®Google Scholar
• Whalen HR, Glen JA, Harkins V, et al. High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime. Transplantation. 2017;101(2):430–436.
   PubMed Web of Science ®Google Scholar
• Vanhove T, Vermeulen T, Annaert P, et al. High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. Am J Transplant. 2016;16(10):2954–2963.
   PubMed Web of Science ®Google Scholar
• Taber DJ, Su Z, Fleming JN, et al. Tacrolimus trough concentration variability and disparities in African American kidney transplantation. Transplantation. 2017;101(12):2931–2938.
   PubMed Web of Science ®Google Scholar
• Sablik KA, Clahsen-van Groningen MC, Hesselink DA, et al. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection. PloS One. 2018;13(5):e0196552.
   PubMed Web of Science ®Google Scholar
• Seibert SR, Schladt DP, Wu B, et al. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant. 2018;32(12):e13424.
   PubMed Web of Science ®Google Scholar
• Rozen-Zvi B, Schneider S, Lichtenberg S, et al. Association of the combination of time-weighted variability of tacrolimus blood level and exposure to low drug levels with graft survival after kidney transplantation. Nephrol Dial Transplant. 2017;32(2):393–399.
   PubMed Web of Science ®Google Scholar
• Leino AD, King EC, Jiang W, et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: establishing baseline values. Am J Transplant [Internet]. DOI:10.1111/ajt.15199
   Google Scholar
• Thölking G, Fortmann C, Koch R, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PloS One. 2014;9(10):e111128.
   PubMed Web of Science ®Google Scholar
• Egeland EJ, Robertsen I, Hermann M, et al. High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation. 2017;101(8):e273–e279.
   PubMed Web of Science ®Google Scholar
• Trofe-Clark J, Brennan DC, West-Thielke P, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis. 2018;71(3):315–326.
   PubMed Web of Science ®Google Scholar
• Niioka T, Kagaya H, Saito M, et al. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations. Clin Exp Nephrol. 2017 Oct;21(5):787–796.
   PubMed Web of Science ®Google Scholar
• Hendijani F, Azarpira N, Kaviani M. Effect of CYP3A5*1 expression on tacrolimus required dose for transplant pediatrics: a systematic review and meta-analysis. Pediatr Transplant. 2018;22(6):e13248.
   Web of Science ®Google Scholar
• Genvigir FDV, Salgado PC, Felipe CR, et al. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients. Pharmacogenet Genomics. 2016;26(10):462–472.
   PubMed Web of Science ®Google Scholar
• Hu R, Barratt DT, Coller JK, et al. CYP3A5*3 and ABCB1 61A>G significantly influence dose‐adjusted trough blood tacrolimus concentrations in the first three months post‐kidney transplantation. Basic Clin Pharmacol Toxicol. 2018 Sep 1;123(3):320–326.
   PubMed Web of Science ®Google Scholar
• Yu M, Liu M, Zhang W, et al. Pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Curr Drug Metab. 2018 mai;19(6):513–522.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326–2333.
   PubMedGoogle Scholar
• Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 1984;311(11):699–705.
   PubMed Web of Science ®Google Scholar
• Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol. 1998;49(6):356–363.
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, PʼNg CH, OʼConnell PJ, et al. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation. 2016;100(8):1723–1731.
   PubMed Web of Science ®Google Scholar
• Snanoudj R, Royal V, Elie CR, et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant. 2011;11(12):2635–2646.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508.
   PubMed Web of Science ®Google Scholar
• Gomes V, Ferreira F, Guerra J, et al. New-onset diabetes after kidney transplantation: incidence and associated factors. World J Diabetes. 2018;9(7):132–137.
   PubMed Web of Science ®Google Scholar
• Mourad G, Glyda M, Albano L, et al. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial. Transplantation. 2017;101(8):1924–1934.
   PubMed Web of Science ®Google Scholar
• Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care. 2002;25(3):583–592.
   PubMed Web of Science ®Google Scholar
• Gupta S, Pollack T, Fulkerson C, et al. Hyperglycemia in the posttransplant period: NODAT vs posttransplant diabetes mellitus. J Endocr Soc. 2018;2(11):1314–1319.
   PubMed Web of Science ®Google Scholar
• Langsford D, Dwyer K. Dysglycemia after renal transplantation: definition, pathogenesis, outcomes and implications for management. World J Diabetes. 2015;6(10):1132–1151.
   PubMed Web of Science ®Google Scholar
• Heisel O, Heisel R, Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4(4):583–595.
   PubMed Web of Science ®Google Scholar
• Torres A, Hernández D, Moreso F, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus. Kidney Int Rep. 2018;3(6):1304–1315.
   PubMed Web of Science ®Google Scholar
• Dedinská I, Ĺ L, Miklušica M, et al. Twelve-month and five-year analyses of risk factors for new-onset diabetes after transplantation in a group of patients homogeneous for immunosuppression. Transplant Proc. 2015;47(6):1831–1839.
   PubMed Web of Science ®Google Scholar
• Song J-L, Li M, Yan L-N, et al. Higher tacrolimus blood concentration is related to increased risk of post-transplantation diabetes mellitus after living donor liver transplantation. Int J Surg Lond Engl. 2018;51:17–23
   PubMed Web of Science ®Google Scholar
• Tillmann FP, Schmitz M, Rump LC, et al. Impact of low-dose steroids on HbA1c levels and development of pre-diabetes and NODAT in non-diabetic renal transplant recipients on long-term follow-up. Int Urol Nephrol. 2018;50(4):771–777.
   PubMed Web of Science ®Google Scholar
• Tufton N, Ahmad S, Rolfe C, et al. New-onset diabetes after renal transplantation. Diabet Med. 2014;31(11):1284–1292.
   PubMed Web of Science ®Google Scholar
• Palepu S, Prasad GVR. New-onset diabetes mellitus after kidney transplantation: current status and future directions. World J Diabetes. 2015;6(3):445–455.
   PubMed Web of Science ®Google Scholar
• Li D-W, Lu T-F, Hua X-W, et al. Risk factors for new onset diabetes mellitus after liver transplantation: a meta-analysis. World J Gastroenterol. 2015;21(20):6329–6340.
   PubMed Web of Science ®Google Scholar
• Quteineh L, Wójtowicz A, Bochud P-Y, et al. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. Am J Transplant. 2019;19(1):238–246.
   PubMed Web of Science ®Google Scholar
• Lancia P, Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetics of posttransplant diabetes mellitus. Pharmacogenomics J. 2017;17(3):209–221.
   PubMed Web of Science ®Google Scholar
• Lancia P, Adam de Beaumais T, Elie V, et al. Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus. Pediatr Nephrol. 2018;33(6):1045–1055.
   PubMed Web of Science ®Google Scholar
• Shi D, Xie T, Deng J, et al. CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients. Eur J Clin Pharmacol. 2018;74(6):723–729.
   PubMed Web of Science ®Google Scholar
• Lombardi A, Trimarco B, Iaccarino G, et al. Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure. Cell Commun Signal. 2017;15(1):47.
   PubMedGoogle Scholar
• Triñanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells. Am J Transplant. 2017;17(11):2829–2840.
   PubMed Web of Science ®Google Scholar
• Fonseca ACRG, Carvalho E, Eriksson JW, et al. Calcineurin is an important factor involved in glucose uptake in human adipocytes. Mol Cell Biochem. 2018;445(1–2):157–168.
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Palming J, Rizell M, et al. Cyclosporine A and tacrolimus reduce the amount of GLUT4 at the cell surface in human adipocytes: increased endocytosis as a potential mechanism for the diabetogenic effects of immunosuppressive agents. J Clin Endocrinol Metab. 2014;99(10):E1885–E1894.
   PubMed Web of Science ®Google Scholar
• Li Z, Sun F, Zhang Y, et al. Tacrolimus induces insulin resistance and increases the glucose absorption in the jejunum: a potential mechanism of the diabetogenic effects. PloS One. 2015;10(11):e0143405.
   PubMed Web of Science ®Google Scholar
• Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7(6):1506–1514.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 déc 20;357(25):2562–2575.
   PubMed Web of Science ®Google Scholar
• Muduma G, Saunders R, Odeyemi I, et al. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PloS One. 2016;11(11):e0160421.
   PubMed Web of Science ®Google Scholar
• Rathi M, Rajkumar V, Rao N, et al. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study. Transplant Proc. 2015;47(4):1158–1161.
   PubMed Web of Science ®Google Scholar
• Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. Am J Transplant. 2018;18(7):1726–1734.
   PubMed Web of Science ®Google Scholar
• Kälble F, Seckinger J, Schaier M, et al. Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. Clin Transplant. 2017;31(8):e13024.
   Web of Science ®Google Scholar
• Song J-L, Gao W, Zhong Y, et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. World J Gastroenterol. 2016;22(6):2133–2141.
   PubMed Web of Science ®Google Scholar
• Wen X, Casey MJ, Santos AH, et al. Comparison of utilization and clinical outcomes for belatacept- and tacrolimus-based immunosuppression in renal transplant recipients. Am J Transplant. 2016;16(11):3202–3211.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Bunnapradist S, Grinyó JM, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in de novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016;67(4):648–659.
   PubMed Web of Science ®Google Scholar
• Bayer ND, Cochetti PT, Anil Kumar MST, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation. 2010 Oct 27;90(8):861–866.
   PubMed Web of Science ®Google Scholar
• Israni AK, Snyder JJ, Skeans MA, et al. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int. 2012 Jul;25(7):748–757.
   PubMed Web of Science ®Google Scholar